News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Investor Alerts Year All Years 2021 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard 11.10.2021 Nuvalent Reports Pipeline Progress and Third Quarter 2021 Financial Results Read More > 10.07.2021 New Preclinical Data Supports Nuvalent Lead Programs in ROS1-Positive, ALK-Positive NSCLC Read More > 09.08.2021 Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results Read More > 08.02.2021 Nuvalent Announces Closing of Upsized Initial Public Offering Read More > 07.28.2021 Nuvalent Announces Pricing of Initial Public Offering Read More > 05.11.2021 Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers Read More > 04.10.2021 Nuvalent Presents Preclinical Data Demonstrating That ROS1 Inhibitor NUV-520 and ALK Inhibitor NUV-655 are Selective, Brain-Penetrant, and Active Against Drug-Resistance Mutations Read More > 03.23.2021 Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer Read More > 01.27.2021 Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers Read More > Show 5102550100 per page
